Literature DB >> 23063776

Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.

Yi-Hui Wu1, Po-Lin Chen2, Yuan-Pin Hung3, Wen-Chien Ko4.   

Abstract

BACKGROUND: Gram-negative bacilli causing community-onset urinary tract infections (CoUTIs) are getting increasingly resistant to antimicrobial agents. Clinical significance and risk factors of the acquisition of antimicrobial-nonsusceptible pathogens are still under investigation.
METHODS: A prospective study was performed in the medical wards of two hospitals in southern Taiwan between August 2009 and January 2012. Patients were enrolled if they were aged >18, admitted through the emergency department, and had CoUTI due to Enterobacteriaceae isolates.
RESULTS: Overall 136 adults with CoUTI were enrolled. Their mean age was 67 years and females were predominant (68.4%). Comorbidities, such as diabetes mellitus (30.1%) and hypertension (54.4%), were common. Escherichia coli (111, 81.6%) was the predominant species, followed by Klebsiella pneumoniae (11, 8.1%), and Proteus mirabilis (7, 5.1%). Nine (8.0%) of E. coli isolates and 5 (45%) of K. pneumoniae isolates had extended-spectrum β-lactamase (ESBL) production. Out of 122 non-ESBL producing isolates, 35 (28.7%) and 31 (25.4%) were nonsusceptible to levofloxacin and cefazolin, respectively. In the multivariate analysis, several clinical characters were found to be independently associated with CoUTIs due to levofloxacin-nonsusceptible (i.e. males, recent hospitalization, underlying old stroke, diabetes mellitus, and altered consciousness, or absence of chills, pyuria, or tachycardia), cefazolin-nonsusceptible (i.e. males, recent hospitalization, underlying old stroke, absence of fever or chills), or ESBL-producing isolates (i.e. recent hospitalization or antimicrobial therapy). All patients survived and discharged. However, the patients with CoUTIs due to levofloxacin-nonsusceptible (16.1 vs. 7.5 days, p < 0.01), cefazolin-nonsusceptible (15.4 vs. 8.4 days, p < 0.01) or ESBL-producing (16.7 vs. 9.6 days; p < 0.01) pathogens had a longer hospitalization stay than those due to their susceptible comparators.
CONCLUSION: Several host factors were recognized to be independently associated with the acquisition of UTIs due to levofloxacin- or cefazolin- nonsusceptible, or ESBL-producing Gram-negative bacilli. The clinical impact of UTIs due to nonsusceptible uropathogens is that they result in the prolongation of hospital stays.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Keywords:  Cefazolin; Clinical impact; Extended-spectrum β-lactamase; Levofloxacin; Nonsusceptibility; Urinary tract infection

Mesh:

Substances:

Year:  2012        PMID: 23063776     DOI: 10.1016/j.jmii.2012.09.001

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  14 in total

1.  Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections.

Authors:  Samantha S Wang; Patrick D Ratliff; William R Judd
Journal:  Int J Clin Pharm       Date:  2017-11-17

Review 2.  Klebsiella pneumoniae: Going on the Offense with a Strong Defense.

Authors:  Michelle K Paczosa; Joan Mecsas
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

3.  [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].

Authors:  Victor M Blanco; Juan J Maya; Adriana Correa; Marcela Perenguez; Juan S Muñoz; Gabriel Motoa; Christian J Pallares; Fernando Rosso; Lorena Matta; Yamile Celis; Martha Garzon; María V Villegas
Journal:  Enferm Infecc Microbiol Clin       Date:  2016-01-13       Impact factor: 1.731

Review 4.  Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Walid Saliba
Journal:  Diabetes Metab Syndr Obes       Date:  2015-02-26       Impact factor: 3.168

5.  The role of Sequence Type (ST) 131 in adult community-onset non-ESBL-producing Escherichia coli bacteraemia.

Authors:  Yi-Hui Wu; Ming-Fang Cheng; Chung-Hsu Lai; Hsi-Hsun Lin; Chih-Hsin Hung; Jiun-Ling Wang
Journal:  BMC Infect Dis       Date:  2014-11-07       Impact factor: 3.090

6.  Bacteriuria and asymptomatic infection in chronic patients with indwelling urinary catheter: The incidence of ESBL bacteria.

Authors:  Sorin Albu; Septimiu Voidazan; Doina Bilca; Monica Badiu; Andreea Truţă; Marian Ciorea; Alin Ichim; Diana Luca; Geanina Moldovan
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

7.  High levels of extended-spectrum beta-lactamases in a major teaching hospital in Ghana: the need for regular monitoring and evaluation of antibiotic resistance.

Authors:  Noah Obeng-Nkrumah; Kingsley Twum-Danso; Karen A Krogfelt; Mercy J Newman
Journal:  Am J Trop Med Hyg       Date:  2013-09-16       Impact factor: 2.345

8.  Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland.

Authors:  E Stefaniuk; U Suchocka; K Bosacka; W Hryniewicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-18       Impact factor: 3.267

9.  Bacteremic Urinary Tract Infection Caused by Multidrug-Resistant Enterobacteriaceae Are Associated With Severe Sepsis at Admission: Implication for Empirical Therapy.

Authors:  Yi-Chien Lee; Chih-Yen Hsiao; Miao-Chiu Hung; Sheng-Che Hung; Hung-Ping Wang; Yun-Jhong Huang; Jann-Tay Wang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  The genetic background of antibiotic resistance among clinical uropathogenic Escherichia coli strains.

Authors:  Wioletta Adamus-Białek; Anna Baraniak; Monika Wawszczak; Stanisław Głuszek; Beata Gad; Klaudia Wróbel; Paulina Bator; Marta Majchrzak; Paweł Parniewski
Journal:  Mol Biol Rep       Date:  2018-07-14       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.